Piper Jaffray Companies reissued their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report released on Monday, December 16th, Stock Target Advisor reports. They currently have a $104.00 price objective on the stock.
Several other brokerages have also issued reports on CRSP. Canaccord Genuity upped their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. Roth Capital upped their target price on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Zacks Investment Research lowered Crispr Therapeutics from a hold rating to a sell rating in a research note on Monday, September 30th. BidaskClub lowered Crispr Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, December 13th. Finally, ValuEngine raised Crispr Therapeutics from a sell rating to a hold rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $71.38.
Shares of CRSP opened at $59.32 on Monday. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s 50-day moving average price is $65.89 and its 200-day moving average price is $51.06. The stock has a market cap of $3.41 billion, a PE ratio of -17.24 and a beta of 3.31. Crispr Therapeutics has a twelve month low of $27.50 and a twelve month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Corporate insiders own 21.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. boosted its position in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after buying an additional 906,006 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at $21,167,000. Price T Rowe Associates Inc. MD boosted its position in shares of Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares during the last quarter. Wells Fargo & Company MN boosted its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC purchased a new position in Crispr Therapeutics in the second quarter worth about $5,165,000. 49.82% of the stock is currently owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Dividend Reinvestment Plan (DRIP)
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.